Synthetic heparin-binding growth factor analogs

Details Synthetic heparin-binding growth factor analogs Synthetic heparin-binding growth factor analogs

2007-01-23

2007-01-23

O'Hara, Eileen (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S085100, C530S397000

Reexamination Certificate

active

10224268

ABSTRACT:
The invention provides synthetic heparin-binding growth factor analogs having at least one peptide chain that binds a heparin-binding growth factor receptor, covalently bound to a hydrophobic linker, which is in turn covalently bound to a non-signaling peptide that includes a heparin-binding domain. The synthetic heparin-binding growth factor analogs are useful as soluble biologics or as surface coatings for medical devices.

REFERENCES:
patent: 5563046 (1996-10-01), Mascarenhas et al.
patent: 5608035 (1997-03-01), Yanofsky et al.
patent: 5635597 (1997-06-01), Barrett et al.
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5648458 (1997-07-01), Cwirla et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5668110 (1997-09-01), Barrett et al.
patent: 5674977 (1997-10-01), Gariepy
patent: 5679637 (1997-10-01), Lappi et al.
patent: 5684136 (1997-11-01), Godowski
patent: 5728802 (1998-03-01), Barrett et al.
patent: 5767234 (1998-06-01), Yanofsky et al.
patent: 5770704 (1998-06-01), Godowski
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5786322 (1998-07-01), Barrett et al.
patent: 5786331 (1998-07-01), Barrett et al.
patent: 5789182 (1998-08-01), Yayon et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5861476 (1999-01-01), Barrett et al.
patent: 5866113 (1999-02-01), Hendriks et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5880096 (1999-03-01), Barrett et al.
patent: 5902799 (1999-05-01), Herrmann et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5952474 (1999-09-01), Kayman et al.
patent: 5955588 (1999-09-01), Tsang et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 5989866 (1999-11-01), Deisher et al.
patent: 5994104 (1999-11-01), Anderson et al.
patent: 6001364 (1999-12-01), Rose et al.
patent: 6011002 (2000-01-01), Pastan et al.
patent: 6030812 (2000-02-01), Bauer et al.
patent: 6051648 (2000-04-01), Rhee et al.
patent: 6121236 (2000-09-01), Ben-Sasson
patent: 6168784 (2001-01-01), Offord et al.
patent: 6174530 (2001-01-01), Rose et al.
patent: 6174721 (2001-01-01), Innis et al.
patent: 6214795 (2001-04-01), Benjamin et al.
patent: 6217873 (2001-04-01), Rose et al.
patent: 6235716 (2001-05-01), Ben-Sasson
patent: 6251864 (2001-06-01), Dower et al.
patent: 6284503 (2001-09-01), Caldwell et al.
patent: 6294359 (2001-09-01), Fiddes et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6342591 (2002-01-01), Zamora et al.
patent: 6350731 (2002-02-01), Jehanli et al.
patent: 6377349 (2002-04-01), Fercher
patent: 6451543 (2002-09-01), Kochendoerfer et al.
patent: WO 00/18921 (2000-04-01), None
patent: WO 02/04015 (2002-01-01), None
patent: WO 02/19963 (2002-03-01), None
patent: WO 02/20033 (2002-03-01), None
Yoneda, et al, 2000, Nature Biotech., 18: 641-644.
Verrecchio, et al, 2000, J. Biol. Chem., 275(11): 7701-7707.
Pellegrini, L., 2001, Cuurent Opinion in Structural Biology, 11: 629-634.
Arne Ostman, Maria Andersson, Ulf Hellman, and Carl-Henrik Heldin, “Identification of Three Amino Acids in the Platelet-derived Growth Factor (PDGF) B-chain that are Important for Binding to the PDGF B-Receptor”The Journal of Biological Chemistry, vol. 266, No. 16, Issue of Jun. 5, pp. 10073-10077, 1991.
David M. Brennand, Ulla Dennehy, Vincent Ellis, Michael F. Scully, Poonam Tripathi, Vijay V. Kakkar, Geeta Patel, Identification of a cyclic peptide inhibitor of platelet-derived growth factor-BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts,FEBS Letters, 413 (1997) 70-74.
Ahmed, Asif; Dunk, Caroline; Kniss, Douglas; Wilkes, Mark, “Role of VEFGF Receptor-1 (Fit-1) in Mediating Calcium-Dependent Nitric Oxide Release and Limiting DNA Synthesis in Human Trophoblast Cells,”Lab Invest, vol. 76(6) Jun. 1997. 779-791.
Philip E. Dawson and Stephen B.H. Kent, “Synthesis of Native Proteins by Chemical Ligation,”Annu. Rev. Biochem. 2000, 69:923-60.
Roselyne Binetruy-Tournaire, Caroline Demangel, Bernard Malavaud, Roger Vassy, Sylvie Rouyre, Michael Kraemer, Jean Plouet, Claude Derbin, Gerard Perret and Jean Claude Mazie, “Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis,”The EMBO Journal, vol. 19 No. 7, pp. 1525-1533, 2000.
Khee Dong Eom, Zhenwei Miao, Jin-Long Yang, and James P. Tam, “Tandem Ligation of Multipartite Peptides with Cell-Permeable Activity,”J. Am. Chem. Soc. 2003, 125, 73-83.
Gerd G. Kochendoerfer, Shiah-Yun Chen, Geng Mao, Sonya Cressman, Stacey Traviglia, Haiyan Shao, Christie L. Hunter, Donald W. Low, E. Neil Cagle, Maia Carnevali, Vincent Gueriguian, Peter J. Keoch, Heather Porter, Stephen M. Stratton, M. Con Wiedeke, Jill Wilken, Jie Tang, Jay J. Levy, Les P. Miranda, Milan M. Crnogorac, Suresh Kalbag, Paolo Botti, Janice Schindler-Horvat, Laura Savatski, John W. Adamson, Ada Kung, Stephen B.H. Kent, James A. Bradburne, “Design and Chemical Synthesis of Homogeneous Polymer-Modified Erythropoiesis Protein,”Science, Feb. 7, 2003, vol. 299.
Ulla Engstrom, Ake Engstrom, Agneta Ernlund, Bengt Westermark, and Carl-Henrik Heldin, “Identification of a Peptide Antagonist for Platelet-derived Growth Factor,”The Journal of Biological Chemistry, vol. 273, No. 25, Issue of Jun. 19, pp. 15811-15817, 1998.
David E. Hoke, Daniel Carson, and Magnus Hook, “A heparin binding synthetic peptide from human HIP/RPL29 fails to specifically differentiate between anticoagulantly active and inactive species of heparin,”Journal of Negative Results in BioMedicine2003, 2:1.
Gay, Cyril G. and Winkles, Jeffrey A.; Interleukin 1 regulates heparin-binding growth facto 2 gene expression in vascular smooth muscle cells; Proc. Natl. Acad. Sci. USA, vol. 88, pp. 296-300, Jan. 1991 Cell Biology.
Peter Carmeliet and Edward M. Conway, “Growing better blood vessels”,Nature Biotechnology(2001) 19:1019-1020.
Thomas P. Richardson, Martin C. Peters, Alessandra B. Ennett, and David J. Mooney, “Polymeric system for dual growth factor delivery”,Nature Biotechnology(2001) 19:1029-1034.
François Paris, Zvi Fuks, Anthony Kang, Paola Capodieci, Gloria Juan, Desiree Ehleiter, Adriana Haimovitz-Friedman, Carlos Cordon-Cardo, Richard Kolesnick, “Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice”,Science(2001) 293:293-297.
Luca Pellegrini, “Role of heparan sulfate in fibroblast growth factor signalling: a structural view”.Structural Biology(2001) 11:629-634.
Takumi Takizawa, Makoto Yanagisawa, Wataru Ochiai, Kiyoshi Yasukawa, Takahiko Ishiguro, Kinichi Nakashima, Tetsuya Taga, “Directly Linked Soluble IL-6 Receptor-IL-6 Fusion Protein Induces Astrocyte Differentiation From Neuroepithelial Cells Via Activation Of STAT3”,Cytokine(2001) 13:272-279.
Atsuko Yoneda, Masahiro Asada, Yuko Oda, Masashi Suzuki, and Toru Imamura, “Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity”,Nature Biotechnology(2000) 18:641-644.
Angela Verrecchio, Markus W. Germann, Barbara P. Schick, Brian Kung, Thomas Twardowski, and James D. San Antonio, “Design of Peptides with High Affinities for Heparin and Endothelial Cell Proteoglycans”,The Journal of Biological Chemistry(2000) 275:7701-7707.
Marcus D. Ballinger, Venkatakrishna Shyamala, Louise D. Forrest, Maja Deuter-Reinhard, Laura V. Doyle, Jian-xin Wang, Lootsee Panganiban-Lustan, Jennifer R. Stratton, Gerald Apell, Jill A. Winter, Michael V. Doyle, Steven Rosenberg, and W. Michael Kavanaugh, “Semirational design of a potent, artificial agonist of fibroblast growth factor receptors”,Nature Biotechnology(1999) 17:1199-1204.
Maemunah Hasan, Saloua Najjam, Myrtle Y. Gordon, Roslyn V. Gibbs, and Christopher C. Rider, “IL-12 is a Heparin-Binding Cytokine”,The Journal of Immunology(1999) 162: 1064-1070.
R. Sood, A. Talwar-Trikha, SR Chakrabarti and G. Nucifora, “MDS1 EVI1 enhances TGF-β1 signaling and strengthen

Affiliated with

Also associated with

Rating

Synthetic heparin-binding growth factor analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic heparin-binding growth factor analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic heparin-binding growth factor analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3774224